Cytokinetics plans supplemental NDA submission for aficamten in Q4 2026
Cytokinetics plans to submit a supplemental NDA to the U.S. FDA for aficamten in Q4 2026.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.